| Ident. | Authors (with country if any) | Title |
|---|
| 002834 (2013) |
Daniel E. Furst [États-Unis] ; Edward Clark Keystone [Canada] ; Alexander K. So [États-Unis, Canada, Allemagne, Pays-Bas, Italie, Royaume-Uni, Autriche] ; Jürgen Braun [Allemagne] ; Ferry C. Breedveld [Pays-Bas] ; Gerd R. Burmester [Italie] ; Fabrizio De Benedetti [Allemagne] ; Thomas Dörner [Allemagne] ; Paul Emery [Royaume-Uni] ; Roy Fleischmann [États-Unis] ; Allan Gibofsky [États-Unis] ; J R Kalden [Allemagne] ; Arthur Kavanaugh [États-Unis] ; Bruce Kirkham [Royaume-Uni] ; Philip Mease [États-Unis] ; A. Rubbert-Roth [Allemagne] ; Joachim Sieper [Allemagne] ; Nora G. Singer [États-Unis] ; Josef S. Smolen [Autriche] ; Piet L C M. Van Riel [Pays-Bas] ; Michael H. Weisman [États-Unis] ; Kevin L. Winthrop [États-Unis] | Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2012 |
| 002867 (2013) |
Tsutomu Takeuchi [Japon] ; Masayoshi Harigai [Japon] ; Yoshiya Tanaka [Japon] ; Hisashi Yamanaka [Japon] ; Naoki Ishiguro [Japon] ; Kazuhiko Yamamoto [Japon] ; Nobuyuki Miyasaka [Japon] ; Takao Koike [Japon] ; Minoru Kanazawa [Japon] ; Takuya Oba [Japon] ; Toru Yoshinari [Japon] ; Daniel Baker [États-Unis] | Golimumab monotherapy in Japanese patients with active rheumatoid arthritis despite prior treatment with disease-modifying antirheumatic drugs: results of the phase 2/3, multicentre, randomised, double-blind, placebo-controlled GO-MONO study through 24 weeks |
| 002868 (2013) |
Josef S. Smolen [Autriche] ; Daniel Aletaha [Autriche] | Forget personalised medicine and focus on abating disease activity |
| 002874 (2013) |
Josef S. Smolen [Autriche] ; Monika M. Schoels [Autriche] ; Norihiro Nishimoto [Japon] ; Ferdinand C. Breedveld [Pays-Bas] ; Gerd R. Burmester [Allemagne] ; Maxime Dougados [France] ; Paul Emery [Royaume-Uni] ; Gianfranco Ferraccioli [Italie] ; Cem Gabay [Suisse] ; Allan Gibofsky [États-Unis] ; Juan Jesus Gomez-Reino [Espagne] ; Graeme Jones [Australie] ; Tore K. Kvien [Norvège] ; Miho Murakami [Japon] ; Neil Betteridge [Royaume-Uni] ; Clifton O. Bingham [États-Unis] ; Vivian Bykerk [Suisse] ; Ernest H. Choy [Royaume-Uni] ; Bernard Combe [France] ; Maurizio Cutolo [Italie] ; Winfried Graninger [Autriche] ; Angel Lanas [Espagne] ; Emilio Martin-Mola [Espagne] ; Carlomaurizio Montecucco [Italie] ; Mikkel Ostergaard [Danemark] ; Karel Pavelka [République tchèque] ; Andrea Rubbert-Roth [Allemagne] ; Naveed Sattar [Royaume-Uni] ; Marieke Scholte-Voshaar [Suisse] ; Yoshiya Tanaka [Japon] ; Michael Trauner [Autriche] ; Gabriele Valentini [Italie] ; Kevin L. Winthrop [États-Unis] ; Maarten De Wit [Pays-Bas] ; Désirée Van Der Heijde [Pays-Bas] | Consensus statement on blocking the effects of interleukin-6 and in particular by interleukin-6 receptor inhibition in rheumatoid arthritis and other inflammatory conditions |
| 002881 (2013) |
Maxime Dougados [France] ; Karsten Kissel [Suisse] ; Tom Sheeran [Royaume-Uni] ; Paul P. Tak [Pays-Bas] ; Philip G. Conaghan [Royaume-Uni] ; Emilio Martín Mola [Espagne] ; Georg Schett [Allemagne] ; Howard Amital [Israël] ; Federico Navarro-Sarabia [Espagne] ; Antony Hou [États-Unis] ; Corrado Bernasconi [Suisse] ; Twj Huizinga [Pays-Bas] | Adding tocilizumab or switching to tocilizumab monotherapy in methotrexate inadequate responders: 24-week symptomatic and structural results of a 2-year randomised controlled strategy trial in rheumatoid arthritis (ACT-RAY) |
| 002917 (2013) |
C. Bengtsson ; L. Padyukov [Suède] ; H. K Llberg ; S. Saevarsdottir [Suède] | THU0514 Thyroxin Substitution and the Risk of Developing Rheumatoid Arthritis; Results from the Swedish Population-Based Eira Study |
| 002931 (2013) |
J. Post Pski ; A. Poluha ; E. Olesi Ska ; P. Sikora [Pologne] | THU0465 Severe Fibrodysplasia Ossificans Progressiva in a 3-Year-Old Girl with Atypical Acvr1 Mutation (G356D) |
| 002996 (2013) |
D. Isenberg [Royaume-Uni] ; C. Gordon [Royaume-Uni] ; D. Licu [Suisse] ; S. Copt [Suisse] ; C. Pena Rossi [Suisse] ; D. Wofsy [États-Unis] | THU0276 Efficacy and Safety of Atacicept for Prevention of Flares in Patients with Moderate to Severe Systemic Lupus Erythematosus (SLE): 52-wk Data (April-SLE Trial) |
| 002A43 (2013) |
H. Yamanaka ; M. Harigai ; S. Inokuma [Japon] ; N. Ishiguro ; J. Ryu [Japon] ; S. Takei ; T. Takeuchi [Japon] ; Y. Tanaka ; Y. Sano [Japon] ; T. Koike [Japon] | THU0092 The advantage of early intervention by tocilizumab for rheumatoid arthritis - full analysis of all-case postmarketing surveillance in 7,901 patients in japan |
| 002B06 (2013) |
S. Bolge ; B. Schenkel ; R. Lorenzo [États-Unis] ; V. Ramesh [États-Unis] ; M. P. Ingham | SAT0482 Role of the rheumatologist in the diagnosis and treatment of rheumatoid arthritis and quality of care from the patient perspective |
| 002B18 (2013) |
J. Homik ; N. Thanh ; A. Ohinmaa ; C. Barnabe [Canada] ; L. Martin [Canada] ; S. Barr [Canada] ; W. Maksymowych | SAT0462 Case definition of serious infection affects incidence and predictors in an inception cohort of rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy |
| 002B47 (2013) |
Y. Saeki ; S. Ohshima ; M. Matsushita ; E. Tanaka-Kudo ; S. Tsuji ; M. Yoshimura ; A. Watanabe ; M. Katayama ; S. Teshigawara ; Y. Katada ; Y. Harada ; A. Yura ; K. Kagawa ; J. Hashimoto ; S. Tohma [Japon] | SAT0144 The Causes of Discontinuation of Biologics(Bio)-Use in the Treatment of Rheumatoid Arthritis (RA) Under Practical Circumstances in Japan: from the “Ninja” Registry |
| 002B61 (2013) |
R. Fleischmann [États-Unis] ; M. Weinblatt [États-Unis] ; M. Schiff ; D. Khanna ; L. Rosenblatt ; M. Maldonado ; D. Furst [États-Unis] | SAT0129 Improved Quality of Life, Work Productivity, General Activity and Independence in Response to Subcutaneous Abatacept or Adalimumab in Rheumatoid Arthritis: Results from the Ample Trial |
| 002B65 (2013) |
M. Harigai ; S. Inokuma [Japon] ; N. Ishiguro ; J. Ryu ; T. Takeuchi [Japon] ; S. Takei ; Y. Tanaka ; H. Yamanaka ; Y. Sano [Japon] ; H. Yaguramaki [Japon] ; T. Koike [Japon] | SAT0120 Characteristics Associated with Better Effectiveness and Safety in Rheumatoid Arthritis Patients Treated with Intravenous Tocilizumab: Results from Full Analysis of All-Patient Postmarketing Surveillance in Japan |
| 002B66 (2013) |
M. Kitano ; S. Kitano ; M. Ishizu ; T. Furukawa ; T. Yoshikawa ; K. Fujita ; Y. Katashima ; C. Sato ; A. Saito ; A. Nishioka ; M. Sekiguchi ; N. Azuma ; N. Hashimoto ; S. Tsunoda ; K. Matsui ; T. Iwasaki [Japon] ; H. Sano | SAT0119 Effect of Abatacept on Bone Homeostasis and Osteopontin in Rheumatoid Arthritis |
| 002B67 (2013) |
M. Hanabayashi [Japon] ; T. Kojima [Japon] ; N. Takahashi [Japon] ; K. Funahashi [Japon] ; D. Kato [Japon] ; Y. Hattori [Japon] ; N. Ishiguro [Japon] | SAT0118 The Clinical Outcome of Abatacept Treatment in Biologic NaÏVe Patients with Rheumatoid Arthritis in Multi-Center Clinical Practice |
| 002D28 (2013) |
T. W. J. Huizinga [Pays-Bas] ; T. Donka [Suisse] ; P. G. Conaghan [Royaume-Uni] ; E. Martin-Mola [Espagne] ; G. Schett [Allemagne] ; H. Amital [Israël] ; R. M. Xavier [Brésil] ; O. Troum [États-Unis] ; C. Bernasconi [Suisse] ; M. Dougados [France] | OP0042 Clinical and Radiographic Outcomes at Two Years and the Effect of Tocilizumab (TCZ) Discontinuation Following Sustained Remission in the Second Year of the Act-Ray Study |
| 002D29 (2013) |
G. Burmester [Allemagne] ; W. Rigby [États-Unis] ; R. Van Vollenhoven [Suède] ; J. Kay [États-Unis] ; A. Rubbert-Roth [Allemagne] ; A. Kelman [États-Unis] ; S. Dimonaco [Royaume-Uni] ; N. Mitchell [Royaume-Uni] | OP0041 Tocilizumab (TCZ) in Combination and Monotherapy Versus Methotrexate (MTX) in MTX-Naive Patients (PTS) with Early Rheumatoid Arthritis (RA): Clinical and Radiographic Outcomes from a Randomised, Placebo-Controlled Trial |
| 002D93 (2013) |
M. Schiff [États-Unis] ; M. Dougados [France] ; R. Fleischmann [États-Unis] ; J. Fay [États-Unis] ; M. Maldonado [États-Unis] | FRI0257 Abatacept and anti-tnf monoclonal antibodies: efficacy and safety comparisons |
| 002D94 (2013) |
M. Genovese ; A. Sebba [États-Unis] ; A. Rubbert-Roth [Allemagne] ; J. Scali [Argentine] ; R. Alten [Allemagne] ; J. Kremer [États-Unis] ; L. Pitts [Royaume-Uni] ; E. Vernon [Royaume-Uni] ; R. Van Vollenhoven [Suède] | FRI0256 Long-term safety of tocilizumab in patients with rheumatoid arthritis following a mean treatment duration of 3.9 years |
| 002D95 (2013) |
L. Quartuccio ; M. Fabris ; E. Pontarini ; S. Salvin ; A. Zabotti ; M. Benucci ; M. Manfredi ; D. Biasi ; V. Ravagnani ; F. Atzeni [Italie] ; P. Sarzi Puttini [Italie] ; P. Morassi ; F. Fischetti ; P. Tomietto ; L. Bazzichi [Italie] ; M. Saracco [Italie] ; R. Pellerito [Italie] ; M. Cimmino ; F. Schiavon ; V. Carraro ; A. Semeraro ; R. Caporali ; L. Cavagna ; R. Bortolotti ; G. Paolazzi ; M. Govoni [Italie] ; S. Bombardieri [Italie] ; S. De Vita | FRI0255 The 158vv fcgamma receptor 3a genotype is associated with response to rituximab in rheumatoid arthritis: results of an italian multicentre study |
